DrugRisk Center: Pradaxa Alternative Approved in Europe Amid Growing Lawsuits

The Drug Risk Resource Center is the Web’s largest source for information on prescription drug research, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Pradaxa Diagram
Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options as soon as possible.

New York, NY (PRWEB) December 07, 2012

The DrugRisk Resource Center is alerting patients taking the blood thinner Pradaxa that an alternative drug Eliquis, which awaits approval in the United States, was recently approved in Europe.

The news comes as the latest report from the Judicial Panel on MultiDistrict Litigation shows the number of Pradaxa lawsuits over internal bleeding has risen 50% since September.*

Yahoo Finance reported on November 21 that Eliquis, which was approved by the European Medicines Agency on November 20, 2012 and is set for hearing with the FDA on March 17, 2013, could take over much of the market of Pradaxa.

Health experts continue to disagree about the safety of Pradaxa and its relation to dangerous or fatal internal bleeding. Last month, the FDA updated its warnings to say that, for now, testing shows Pradaxa carries the same risks as warfarin and Coumadin.** However, the New York Times published a story the same day detailing concerns of doctors that Pradaxa led all other medications for adverse reports and currently has no antidote for internal bleeding.***

Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options as soon as possible.

Due to the growing number of Pradaxa lawsuits, cases have been moved to a special federal court in Illinois. The formal case is known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

U.S. District Judge David Herndon, who presides over the nationwide Pradaxa lawsuits, recently ordered that manufacturer Boehringer Ingelheim will have until December 17th to produce evidence disputing claims that the drug can cause dangerous or fatal bleeding.****

Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.

For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets-By-District-November-2012.pdf
**fda.gov/Drugs/DrugSafety/ucm326580.htm
***nytimes.com/2012/11/03/business/a-rising-anti-stroke-drug-is-tied-to-risk-of-bleeding-deaths.html
****ilsd.uscourts.gov/opinions/ilsd_live.3.12.md.2385.2208479.0.pdf#search=%22pradaxa%22


Contact